ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Inhibition of junctional protein disruption by 2,4,6-trihydroxy-3-geranyl acetophenone in lipopolysaccharide-induced endothelial hyperpermeability via GEF-H1/RhoA/ROCK pathway.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
2,4,6-Trihydroxy-3-geranyl acetophenone (tHGA) is a bioactive phloroglucinol compound found in the leaves of Melicope pteleifolia (Champ. ex Benth.) T.G.Hartley. Our previous study has proven that tHGA exhibited significant in vitro barrier protective effects against lipopolysaccharide (LPS) induction, mainly by inhibiting endothelial hyperpermeability via attenuation of F-actin cytoskeletal rearrangement, as F-actin cytoskeleton is anchored to junctional proteins such as zonula occluden (ZO)-1, occludin, and vascular endothelial-cadherin (VE-cadherin), and they play collaborative roles in the preservation of endothelial integrity. Therefore, the effects of tHGA on these junctional proteins were further investigated, followed by the dissection of signalling pathways mediated by tHGA in suppressing LPS-induced junctional protein disruption during endothelial hyperpermeability. HUVECs were pretreated with tHGA prior to LPS induction. TEER, immunofluorescence staining, Western Blotting, and RT-qPCR were performed to examine the effects of tHGA on junctional proteins in terms of their integrity, localization, protein expression, and gene expression, respectively. Proinflammatory signalling molecules including MLC, NF-κB p65, p38 MAPK, ERK MAPK, and JNK MAPK were assessed to unravel the underlying signalling pathways, followed by molecular docking on human ROCK1 to predict the molecular target of tHGA. tHGA profoundly preserved junctional integrity by inhibiting both delocalization and downregulation of ZO-1, occludin, and VE-cadherin, via inactivation of MLC, NF-κB p65, p38 MAPK, and ERK MAPK, which are mainly diverged from GEF-H1/RhoA/ROCK pathway. ROCK1 was predicted as the molecular target of tHGA. tHGA should be developed as a potential therapeutic remedy for prevention and/or treatment of permeability-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.